What we offer
The University of Lausanne (UNIL) is offering an International Master in Vaccinology (IMVACC) developed by the Swiss Vaccine Research Institute (SVRI) and the Health Sciences e-Training Foundation (HSeT) in collaboration with the Lausanne University Hospital (CHUV).
What you get
IMVACC comprises one year of on-line teaching of vaccinology followed by a six months to one year master thesis on a vaccine-related activity (industry, basic or translational research, regulatory affairs, etc.). The thesis project can be carried out in the trainee’s institution or in a hosting laboratory. Graduates will gain a broad knowledge of how vaccines are designed, developed, manufactured and implemented through public health programs.
Covid-19 and vaccine development
With the Covid-19 pandemic, IMVACC has added SARS-CoV-2 to its existing section on coronaviruses that already included SARS-CoV-1 and MERS-CoV. The new content includes information on the biology of the coronaviruses, the spread of COVID-19 across the globe, and strategies to contain it. Links to the most relevant sources of information and to important publications are also included. The content is updated weekly and is available to all IMVACC students.
The 16 students have registered and started the program by completing the prerequisites and the associated quizzes. They met on January 13-15 2020 for a kickoff meeting in Lausanne during which they have been trained in the use of the Moodle eLearning platform and on how to perform team work at distance.
Due to load shedding to prevent an imbalance in electricity supply and subsequent blackout in South Africa, our South African students download the IMVACC modules to work on a standalone mode and use candles to see their keyboard.
IMVACC class 2019.
The 8 students have completed the first year and successfully passed the final exam. They are now starting their master thesis project.
IMVACC Class 2018.
The 5 trainees have completed the first year and passed the final exam in January 2019. They are currently working on their master thesis project. They will defend their master thesis during the year
IMVACC Class 2016.
All students have completed the master program and have received 60 ECTS credits and the diploma from the Lausanne University. The thesis work of Nicolas Peyraud has been published in Vaccine (2019. 37:4427-4434) with the title “Potential use of microarray patches for vaccine delivery in low- and middle- income countries”.
The documentary “Vaccines why are they scary” (Les Vaccins pourquoi font-ils peur) has been presented on October within the Swiss medical television documentary program “36.9” created by Isabelle Moncada. Alain Meystre from the Health Sciences eTraining Foundation (HSeT) has created the English subtitles.
Why do some parents worry about getting their children vaccinated? Where does this fear come from? 36.9 ° went to meet those who doubt. To get out of mistrust and sterile debates between pro and anti-vaccines, it is worthwhile to examine them separately, vaccine by vaccine, in light of the benefits and risks of each.
To develop the vaccines of the future
To develop a network of vaccinologists
To contribute more efficiently to the development of vaccines, IMVACC students will be provided with the opportunity to work on real-life questions and situations encountered in vaccine development and to develop their professional network. They will gain broad scientific, strategic and technical experience applicable to their work environment. Vaccine experts are also needed to help counter the rising skepticism of people regarding the safety and efficacy of vaccines.
To foster interactions between the IMVACC trainees, an IMVACC online portal will be set up shortly to allow all the students, former and present, to view updates of the course and to share their experience
For professionals in medical sciences
Tutor-assisted on-line teaching
“With its on-line, tutor-supported teaching approach, IMVACC offers a new way to train students in vaccinology across the World. It fits well with the goal of WHO to build capacity for science and research, especially in low- and middle-income countries.”
Dr Marie-Paule Kieny, former Assistant Director-General, WHO, Geneva